US 10350239
Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
granted A61KA61K2300/00A61K31/095
Quick answer
US patent 10350239 (Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent) held by Propanc Pty Ltd expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Propanc Pty Ltd
- Grant date
- Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K2300/00, A61K31/095, A61K31/21, A61K33/04